Jasper Therapeutics, Inc. (JSPR) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US4718712023
Price
10.34 USD
Market cap
11.47 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–
Jasper Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -83.88 m USD |
| EBIT | -77.54 m USD |
| Net income | -75.80 m USD |
| Diluted EPS – continuing operations | -3.95 USD |
Full history since 2019, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Jasper Therapeutics, Inc.
Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of biologic agents to enhance the outcomes in patients with immunologically-driven disorders. The company is based in Redwood City, California.
More stocks
- EON Resources Inc. (EONR)
- ACCESS Newswire Inc. (ACCS)
- Foreveren (FOR.WA)
- TerraVolt Holdings, Inc. (GEDC)
- Aligos Therapeutics, Inc. (ALGS)
- DYADIC INTERNATIONAL INC (DYAI)
- BARFRESH FOOD GROUP INC. (BRFH)
- Bridger Aerospace Group Holdings, Inc. (BAER)
- SUNation Energy, Inc. (SUNE)
- Fold Holdings, Inc. (FLD)
- eHealth, Inc. (EHTH)
- BARNWELL INDUSTRIES INC (BRN)
Not investment advice. All data without warranty, price as of 17.11.2026. Details in the risk notice.